Table 1 Clinicopathological profile of glioblastoma patients in cohort A and cohort B cohorts

Diagnostic^a

PD

41

(37.2)

18

(50)

psPD

15

(37.7)

18

(50)

Gender^a

Male

35

(62.5)

24

(66.6)

Female

21

(37.5)

12

(33.3)

Age (years)^b

62

(13.7)

67

(10.0)

BMI^b

27.9

(9.2)

29.1

(8.2)

Side^c

Left

28

(50.0)

21

(58.4)

Right

28

(50.0)

15

(41.6)

Lesion Size (cm)^c

4.1

(1.8)

4.0

(2.0)

Lobe Location^a

Frontal

21

(37.5)

8

(22.2)

Occipital

0

(0)

5

(13.8)

Parietal

16

(28.5)

8

(22.2)

Temporal

19

(33.9)

15

(41.6)

Midline Shift^a

Yes

23

(41.1)

10

(27.7)

No

33

(58.9)

26

(72.3)

Ki-67 Positive Percent^b

30.0

(20.0)

27.5

(22.2)

MGMT Status^a

Hypermethylated/ Methylated

23

(41.1)

18

(50.0)

Not Hypermethylated/ Unmethylated

33

(58.9)

18

(50.0)

EGFR Amplification^a

No

29

(70.7)

19

(59.4)

Yes

12

(29.3)

13

(40.6)

P53 Mutation Status (> 10% of Cells)^a

Negative

11

(22.0)

7

(20.6)

Positive

39

(78.0)

27

(79.4)

WBC (Pre-surgery)^b

11.2

(6.5)

9.1

(4.6)

Hemoglobin (Pre-surgery)^c

14.1

(2.3)

14.5

(1.8)

Platelets (Pre-surgery)^c

247.8

(71.9)

233.4

(61.1)

Neutrophils (Segs + Bands) (Pre-surgery)^c

9.2

(4.2)

7.8

(4.4)

Lymphocytes (Pre-surgery)^c

1.2

(0.7)

1.4

(0.6)

Number of Gy administered^a

40

5

(8.9)

4

(11.1)

60

51

(91.1)

32

(88.9)

Number of Gy Fractions^a

15

5

(8.9)

4

(11.1)

30

51

(91.1)

32

(88.9)

Cycles Completed^b

5

(5.0)

5.5

(3.0)

Adjuvant Temodar Dose^b

280

(190.0)

355

(106.2)